MP
SRRA

Mangrove Partners’s Sierra Oncology, Inc. Common Stock SRRA Stock Holding History

Mangrove Partners’s Portfolio SRRA Stock Details SRRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-108,914
Closed -$1.75M – 369
2020
Q4 		$1.75M Sell
108,914
-304,895
-74% -$4.23M 0.24% 66
2020
Q3 		$4.42M Sell
413,809
-7,280
-2% -$86.7K 0.56% 37
2020
Q2 		$5.09M Sell
421,089
-18,443
-4% -$229K 1.24% 27
2020
Q1 		$4.32M Buy
+439,532
New +$5.76M 0.6% 32
2019
Q4 		– Sell
-92,215
Closed -$1.44M – 101
2019
Q3 		$1.44M Hold
92,215
– – 0.17% 67
2019
Q2 		$2.07M Hold
92,215
– – 0.23% 54
2019
Q1 		$6.31M Hold
92,215
– – 0.84% 28
2018
Q4 		$4.87M Buy
92,215
+80,034
+657% +$5.11M 0.65% 34
2018
Q3 		$828K Buy
+12,181
New +$1.1M 0.05% 35

Other funds holding SRRA

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
CC
Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return

Mangrove Partners's SRRA Position: Q1 2021 in Review

Mangrove Partners sold out of Sierra Oncology, Inc. Common Stock (SRRA) in Q1 2021, closing a stake of 108,914 shares — an estimated $1.75M sold.

Mangrove Partners first reported a position in SRRA in Q3 2018 and held it in 9 quarters. The position peaked at $6.31M in Q1 2019. 33 funds tracked by Wall St. Rank hold SRRA as of Q1 2021.

  • Mangrove Partners reported no remaining Sierra Oncology, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • Mangrove Partners sold 108,914 Sierra Oncology, Inc. Common Stock shares in Q1 2021, an estimated $1.75M.
  • Mangrove Partners first reported a position in Sierra Oncology, Inc. Common Stock in Q3 2018 and held it in 9 quarters.
  • Mangrove Partners's Sierra Oncology, Inc. Common Stock position peaked at $6.31M in Q1 2019.
  • 33 funds tracked by Wall St. Rank held Sierra Oncology, Inc. Common Stock as of Q1 2021.

Based on Mangrove Partners's 13F filing for Q1 2021, filed 17 May 2021.